Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

Medicine & Life Sciences

• Antiviral Agents 4%
• benzimidazole 7%
• Cytomegalovirus 37%
• Cytomegalovirus Infections 59%
• Duration of Therapy 5%
• Emergencies 4%
• Ganciclovir 6%
• Hematopoietic Stem Cells 5%
• Investigational New Drug Application 9%
• maribavir 100%
• Mutation 3%
• Pharmaceutical Preparations 2%
• Physicians 3%
• Pneumonia 4%
• Research Ethics Committees 5%
• Safety 3%
• Serum 2%
• Therapeutics 8%
• Transplant Recipients 50%
• Transplants 6%
• United States Food and Drug Administration 5%
• Viral Load 5%